Summary & Overview

HCPCS G9649: Psoriasis Assessment Tool Documentation

HCPCS Level II code G9649 denotes documentation that a standardized psoriasis assessment tool met any one of specified benchmarks, such as Physician Global Assessment (PGA), Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), or Dermatology Life Quality Index (DLQI). The code captures objective and patient-reported measures used to assess disease severity and treatment response for psoriasis in outpatient dermatology or similar ambulatory settings. Nationally, standardized assessment documentation supports clinical decision-making, care continuity, quality measurement, and payer coverage determinations for systemic and advanced therapies.

Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical intent and typical use cases, guidance on common service settings, and a roadmap of topics covered elsewhere in the publication: payer coverage patterns and benchmarks, policy and coding clarifications, clinical context on commonly used assessment instruments, and operational considerations for documenting and billing.

Where input data is incomplete, the publication notes missing items as "Data not available in the input." The content is aimed at clinicians, revenue cycle staff, and policy analysts seeking a national perspective on documentation and coding for psoriasis severity assessment.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9649HCPCS Level IIpsoriasis assessmentdermatologydisease severityPASIDLQIclinical documentationoutpatient ambulatory

Billing Code Overview

HCPCS Level II code G9649 documents use of a psoriasis assessment tool when any one of the specified benchmarks is recorded. Examples of acceptable tools include the Physician Global Assessment (PGA; 5-point or 6-point scale), Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), and the Dermatology Life Quality Index (DLQI).

Service Type: Disease severity and treatment response assessment for psoriasis

Typical Site of Service: Dermatology clinic or outpatient ambulatory setting

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with chronic plaque psoriasis presenting to dermatology for disease activity assessment to guide therapy decisions. The visit includes symptom review, skin exam, and administration of a standardized psoriasis assessment tool such as the Physician Global Assessment (pga using a 5- or 6-point scale), Body Surface Area (bsa) estimation, Psoriasis Area and Severity Index (pasi), and/or Dermatology Life Quality Index (dlqi). Documentation must record meeting any one of the specified benchmarks to support billing of G9649. The clinical workflow commonly follows: patient check-in and brief history focusing on recent flares, current treatments, and impact on daily life; nurse or medical assistant documents baseline photos and assists with dlqi questionnaire; clinician performs targeted skin exam, calculates bsa and/or pasi, assigns pga score, and records findings in the chart. Results are used to justify treatment initiation, escalation, biologic therapy continuation, or referral to specialty care. Typical sites of service include dermatology clinic, outpatient physician office, and specialty infusion centers when linked to treatment monitoring. Typical patient scenario: a 42-year-old patient with moderate plaque psoriasis on methotrexate presents for follow-up; the dermatologist documents a pga score of 3 (moderate) and bsa 8%, completes dlqi showing significant life-quality impact, and records these benchmarks to support billing for standardized psoriasis assessment.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when the psoriasis assessment required substantially greater work than usual (extensive counseling or complex documentation tied to assessment).
`23`	Unusual anesthesia	Rarely used for this service; only if unusual anesthesia unrelated to the assessment is provided during the visit.
`52`	Reduced services	Use when a limited assessment was performed and full assessment benchmarks could not be completed.
`53`	Discontinued procedure	Use if assessment was started but discontinued due to patient condition or other valid reason.
`54`	Surgical care only	Not typically applicable; use when only perioperative care is billed separately and assessment is not part of global surgical package.
`55`	Postoperative care only	Not typically applicable; use when only postop care is provided and assessment is separate.
`56`	Preoperative care only	Use when the assessment was performed solely as preoperative evaluation for dermatologic surgery.
`62`	Two surgeons	Use when two surgeons share responsibility for a surgical case and the assessment is documented by one surgeon in that context.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Use if an advanced practice clinician documents the assessment as part of assistant-at-surgery services.
`CO`	Services related to a Clinical Research Organization (CRO) study	Use when assessment is performed under a CRO-sponsored clinical trial and documented per CRO requirements.
`CQ`	Service furnished as part of a clinical trial qualifying for non-coverage	Use when assessment is billed but the trial is non-covered; follows applicable billing rules.
`FX`	Split/shared E/M — non-physician	Use when a split/shared visit occurs and the non-physician documents the assessment for billing purposes.
`FY`	Split/shared E/M — physician	Use when a split/shared visit occurs and the physician documents the assessment for billing purposes.
`QK`	Medical direction of two, three, or four concurrent anesthesia procedures	Not commonly used for this code; included only if anesthesia services are concurrently directed during an associated procedure.
`QX`	CRNA service with medical direction	As above, rarely applicable; only when assessment is contemporaneous with anesthesia care.

Taxonomy Code	Specialty	Notes
`207N00000X`	Dermatology	Primary specialty performing psoriasis assessments and documenting `pga`, `bsa`, `pasi`, `dlqi`.
`363L00000X`	Physician Assistant	Common providers who perform and document assessments under dermatology supervision.
`352600000X`	Nurse Practitioner	Advanced practice providers frequently conducting assessments and completing `dlqi` documentation.
`208D00000X`	Dermatopathology	May be involved for biopsy correlation; documents findings that can inform severity assessments.

ICD-10 Code	Description	Clinical Relevance
`L40.0`	Psoriasis vulgaris	Primary diagnosis for which standardized psoriasis assessment tools (`pga`, `bsa`, `pasi`, `dlqi`) are applied to quantify disease severity and guide therapy.
`L40.8`	Other psoriasis	Used for less common psoriasis variants where assessment still documents extent and impact.
`L40.9`	Psoriasis, unspecified	Used when psoriasis is documented but subtype not specified; assessment supports severity coding and management.
`L40.5`	Arthropathic psoriasis	Relevant when psoriatic arthritis is present; skin severity assessment informs systemic therapy decisions coordinated with rheumatology.
`B35.3`	Tinea corporis	Included as a differential diagnosis code; occasionally used when distinguishing psoriasis from fungal infections during assessment (clinically relevant for documentation).

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M code used when the psoriasis assessment is part of a focused follow-up visit; documents medical decision-making incorporating `pga`/`bsa`/`pasi` results.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used when the visit includes moderate to high complexity decision-making based on assessment results, treatment changes, or biologic therapy management.
`96900`	Phototherapy, ultraviolet B (UVB), per course of therapy	May be ordered or managed following documented severity assessment; not billed concurrently for the assessment but often related in workflow.
`11100`	Biopsy of skin, single lesion	Performed when assessment indicates unclear diagnosis or for histologic confirmation; precedes or follows severity assessment in diagnostic workflow.
`97035`	Electrical stimulation (unattended)	Data not typically related; include only if adjunctive modalities are provided in same episode — otherwise not commonly used.

OpenPayer